MARTA ISABEL
SIERRA ZAPICO
Investigadora
Instituto Universitario de Oncologia del Principado de Asturias
Oviedo, EspañaPublications en collaboration avec des chercheurs de Instituto Universitario de Oncologia del Principado de Asturias (20)
2020
-
Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis
International Journal of Cancer, Vol. 146, Núm. 2, pp. 373-387
2019
-
Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment
Nucleic Acids Research, Vol. 47, Núm. 10, pp. 5016-5037
2018
-
DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase
Epigenetics, Vol. 13, Núm. 1, pp. 95-107
-
Epigenetic dysregulation of TET2 in human glioblastoma
Oncotarget, Vol. 9, Núm. 40, pp. 25922-25934
-
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
Nature, Vol. 554, Núm. 7690, pp. 62-68
-
Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma
Human Molecular Genetics, Vol. 27, Núm. 17, pp. 3046-3059
2017
-
Cisplatin resistance in cell models evaluation of metallomic and biological predictive biomarkers to address early therapy failure
Metallomics, Vol. 9, Núm. 5, pp. 564-574
-
DNA methylation changes in human lung epithelia cells exposed to multi-walled carbon nanotubes
Nanotoxicology, Vol. 11, Núm. 7, pp. 857-870
2016
-
Age-associated hydroxymethylation in human bone-marrow mesenchymal stem cells
Journal of Translational Medicine, Vol. 14, Núm. 1
-
Susceptibility of lactic acid bacteria, bifidobacteria and other bacteria of intestinal origin to chemotherapeutic agents
International Journal of Antimicrobial Agents, Vol. 48, Núm. 5, pp. 547-550
2013
-
Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictiv
Mutagenesis, Vol. 28, Núm. 1, pp. 39-48
2011
-
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: A phase Ib study
International Journal of Gynecological Cancer, Vol. 21, Núm. 3, pp. 478-485
-
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
Investigational New Drugs, Vol. 29, Núm. 5, pp. 971-977
2006
-
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study
British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802
-
Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 840, Núm. 1, pp. 44-49
2005
-
Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: A preliminary study on cancer patients
Journal of Pharmaceutical and Biomedical Analysis
-
Development and validation of an ion pair HPLC method for gemcitabine and 2′,2′-difluoro-2′-deoxyuridine determination
Analytica Chimica Acta, Vol. 528, Núm. 2, pp. 255-260
2004
-
Determination of gemcitabine triphosphate in peripheral blood mononuclear cells by reverse-phase HPLC
Chromatographia, Vol. 59, Núm. 7-8, pp. 493-496
-
Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation
Cancer, Vol. 101, Núm. 10, pp. 2261-2269
-
Protein kinase C θ is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias
Clinical Cancer Research, Vol. 10, Núm. 12 I, pp. 4089-4095